Cara Therapeutics Inc Banner Image

Cara Therapeutics Inc

  • Ticker CARA
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Cara Therapeutics Inc Logo Image
  • 51-200 Employees
  • Based in Stamford, Connecticut
Cara Therapeutics is a commercial-stage biopharmaceutical company leading a new treatment to improve the lives of patients suffering from pruritus. The company’s novel KORSUVA™ (difelikefalin) injection is the first and only FDA and EMA approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. The company is developing anMore oral formulation of difelikefalin for the treatment of pruritus in patients with non-dialysis dependent advanced chronic kidney disease, atopic dermatitis, and notalgia paresthetica.
4.8 / 5.0 (177)

Cara Therapeutics Inc reports have an aggregate usefulness score of 4.8 based on 177 reviews.

Cara Therapeutics Inc

Most Recent Annual Report

Cara Therapeutics Inc
MOST RECENT 2023 Annual Report and Form 10K

Cara Therapeutics Inc does not currently have any hardcopy reports on AnnualReports.com. Click the button below to request a report when hardcopies become available.

Request Information

Older/Archived Annual Reports

Cara Therapeutics Inc Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!